Overview of the 2022 WHO classification of adrenal cortical tumors

O Mete, LA Erickson, CC Juhlin, RR de Krijger… - Endocrine …, 2022 - Springer
The new WHO classification of adrenal cortical proliferations reflects translational advances
in the fields of endocrine pathology, oncology and molecular biology. By adopting a …

Approach to the patient with adrenal incidentaloma

I Bancos, A Prete - The Journal of Clinical Endocrinology & …, 2021 - academic.oup.com
Adrenal tumors are commonly discovered incidentally on cross-sectional abdominal
imaging performed for reasons other than adrenal mass. Incidence of adrenal tumors …

European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the …

M Fassnacht, S Tsagarakis, M Terzolo… - European Journal of …, 2023 - academic.oup.com
Adrenal incidentalomas are adrenal masses detected on imaging performed for reasons
other than suspected adrenal disease. In most cases, adrenal incidentalomas are …

Neuroendocrine and adrenal tumors, version 2.2021, NCCN clinical practice guidelines in oncology

MH Shah, WS Goldner, AB Benson… - Journal of the National …, 2021 - jnccn.org
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Neuroendocrine
and Adrenal Gland Tumors focus on the diagnosis, treatment, and management of patients …

Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up

M Fassnacht, G Assie, E Baudin… - Annals of …, 2020 - annalsofoncology.org
Two different primary malignancies can arise from the adrenal gland: adrenocortical
carcinoma (ACC) from the adrenal cortex and malignant phaeochromocytoma from the …

Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study

I Bancos, AE Taylor, V Chortis, AJ Sitch… - The lancet Diabetes & …, 2020 - thelancet.com
Background Cross-sectional imaging regularly results in incidental discovery of adrenal
tumours, requiring exclusion of adrenocortical carcinoma (ACC). However, differentiation is …

MicroRNA therapeutics in cancer: current advances and challenges

S Reda El Sayed, J Cristante, L Guyon, J Denis… - Cancers, 2021 - mdpi.com
Simple Summary Cancer is a complex disease associated with deregulation of numerous
genes. In addition, redundant cellular pathways limit efficiency of monotarget drugs in …

CDK1 serves as a therapeutic target of adrenocortical carcinoma via regulating epithelial–mesenchymal transition, G2/M phase transition, and PANoptosis

L Ren, Y Yang, W Li, X Zheng, J Liu, S Li… - Journal of translational …, 2022 - Springer
Background Adrenocortical carcinoma (ACC) is an extremely rare, aggressive tumor with
few effective therapeutic options or drugs. Mitotane (Mtn), which is the only authorized …

Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the Children's Oncology Group ARAR0332 …

C Rodriguez-Galindo, MD Krailo, EM Pinto… - Journal of Clinical …, 2021 - ascopubs.org
PURPOSE Adrenocortical carcinoma (ACC) is a rare aggressive pediatric malignancy with
distinct biology. Its treatment follows the principles developed for adults; pediatric-specific …

Cushing syndrome: a review

M Reincke, M Fleseriu - Jama, 2023 - jamanetwork.com
Importance Cushing syndrome is defined as a prolonged increase in plasma cortisol levels
that is not due to a physiological etiology. Although the most frequent cause of Cushing …